$NAUT

Nautilus Biotechnology (NAUT) Upgraded to Buy: Here's What You Should Know

Zacks Investment Research · 5/3/2024, 4:00:09 PM

Nautilus Biotechnology (NAUT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Nautilus Biotechnology Reports First Quarter 2024 Financial Results

GlobeNewswire Inc. · 4/30/2024, 12:00:00 PM

SEATTLE, April 30, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financial results for the first quarter ended March 31, 2024.

Nautilus Biotechnology to Participate in the TD Cowen 44ᵗʰ Annual Healthcare Conference

GlobeNewswire Inc. · 2/22/2024, 1:00:00 PM

SEATTLE, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the TD Cowen 44th Annual Healthcare Conference.

Nautilus Biotechnology Appoints Martin Huber, Ph.D., as Vice President of Biochemistry and Flow Cell Development

GlobeNewswire Inc. · 11/1/2023, 12:05:00 PM

Former Quantapore founder and CEO brings 20 years of proteomics and genomics industry experience to company developing a platform for comprehensively quantifying the proteome Former Quantapore founder and CEO brings 20 years of proteomics and genomics industry experience to company developing a platform for comprehensively quantifying the proteome

Nautilus Biotechnology Reports Third Quarter 2023 Financial Results

GlobeNewswire Inc. · 10/31/2023, 12:05:00 PM

SEATTLE, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financial results for the third quarter ended September 30, 2023.